NASDAQ:HTGM - HTG Molecular Diagnostics Stock Price, Price Target & More

$3.53 +0.06 (+1.73 %)
(As of 04/25/2018 04:00 PM ET)
Previous Close$3.53
Today's Range$3.4301 - $3.53
52-Week Range$1.59 - $5.83
Volume293,094 shs
Average Volume1.79 million shs
Market Capitalization$96.13 million
P/E Ratio-1.97
Dividend YieldN/A
Beta1.63

About HTG Molecular Diagnostics (NASDAQ:HTGM)

HTG Molecular Diagnostics logoHTG Molecular Diagnostics, Inc. develops and markets products and services based on proprietary technology that facilitates the routine use of targeted molecular profiling. The company's products, HTG Edge and HTG EdgeSeq platforms include instrumentation (or platforms), consumables comprising assay kits, and software analytics that automate sample processing and profiles various molecular targets from samples a fraction of the size required by prevailing technologies. Its platforms generate a molecular profiling library for detection using next-generation sequencing. The company's assay product offerings include HTG EdgeSeq oncology biomarker panel; HTG EdgeSeq immuno-oncology assay; HTG EdgeSeq lymphoma panel; HTG EdgeSeq microRNA whole-transcriptome assay; and HTG EdgeSeq DLBCL cell of origin assay. It also provides sample processing and molecular profiling of retrospective cohorts through its VERI/O laboratory; and designs custom panels for biopharmaceutical customers and research services, resulting from research and development collaboration agreements with biopharmaceutical customers. It serves biopharmaceutical companies, academic research centers, and molecular testing laboratories. The company has a research collaboration with Insituto Valenciano de Oncologia on breast cancer recurrence risk. HTG Molecular Diagnostics, Inc. distributes its instruments and consumables directly in the United States and Europe; and through distributors in parts of Europe and internationally. The company was formerly known as HTG, Inc. and changed its name to HTG Molecular Diagnostics, Inc. in March 2011. HTG Molecular Diagnostics, Inc. was incorporated in 1997 and is based in Tucson, Arizona.

Receive HTGM News and Ratings via Email

Sign-up to receive the latest news and ratings for HTGM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Analytical instruments
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:HTGM
CUSIPN/A
Phone877-289-2615

Debt

Debt-to-Equity RatioN/A
Current Ratio1.34%
Quick Ratio1.26%

Price-To-Earnings

Trailing P/E Ratio-1.97
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$14.76 million
Price / Sales6.78
Cash FlowN/A
Price / CashN/A
Book Value($0.12) per share
Price / Book-29.42

Profitability

EPS (Most Recent Fiscal Year)($1.79)
Net Income$-18,960,000.00
Net Margins-128.46%
Return on EquityN/A
Return on Assets-109.14%

Miscellaneous

Employees98
Outstanding Shares28,360,000

How to Become a New Pot Stock Millionaire

HTG Molecular Diagnostics (NASDAQ:HTGM) Frequently Asked Questions

What is HTG Molecular Diagnostics' stock symbol?

HTG Molecular Diagnostics trades on the NASDAQ under the ticker symbol "HTGM."

How were HTG Molecular Diagnostics' earnings last quarter?

HTG Molecular Diagnostics (NASDAQ:HTGM) announced its earnings results on Thursday, March, 22nd. The medical research company reported ($0.15) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.30) by $0.15. The medical research company had revenue of $7.90 million for the quarter, compared to the consensus estimate of $7.05 million. View HTG Molecular Diagnostics' Earnings History.

When is HTG Molecular Diagnostics' next earnings date?

HTG Molecular Diagnostics is scheduled to release their next quarterly earnings announcement on Monday, May, 14th 2018. View Earnings Estimates for HTG Molecular Diagnostics.

What price target have analysts set for HTGM?

3 brokers have issued 12 month target prices for HTG Molecular Diagnostics' stock. Their predictions range from $6.00 to $7.00. On average, they anticipate HTG Molecular Diagnostics' stock price to reach $6.6667 in the next twelve months. View Analyst Ratings for HTG Molecular Diagnostics.

Who are some of HTG Molecular Diagnostics' key competitors?

Who are HTG Molecular Diagnostics' key executives?

HTG Molecular Diagnostics' management team includes the folowing people:
  • Mr. Timothy B. Johnson, Pres, CEO & Director (Age 57)
  • Mr. John L. Lubniewski, VP & Chief Bus. Officer (Age 54)
  • Dr. Patrick C. Roche Ph.D., Sr. VP of Research & Product Devel. (Age 65)
  • Mr. Shaun D. McMeans, VP of Fin. & Admin, Treasurer & CFO (Age 56)
  • Dr. Debra A. Gordon Ph.D., J.D., VP, Chief Legal Counsel & Sec. (Age 58)

When did HTG Molecular Diagnostics IPO?

(HTGM) raised $50 million in an IPO on Wednesday, May 6th 2015. The company issued 3,600,000 shares at a price of $13.00-$15.00 per share. Leerink Partners acted as the underwriter for the IPO and Canaccord Genuity and JMP Securities were co-managers.

Has HTG Molecular Diagnostics been receiving favorable news coverage?

News headlines about HTGM stock have trended somewhat positive this week, Accern Sentiment reports. The research firm ranks the sentiment of news coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. HTG Molecular Diagnostics earned a media sentiment score of 0.21 on Accern's scale. They also gave media stories about the medical research company an impact score of 44.94 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

How do I buy shares of HTG Molecular Diagnostics?

Shares of HTGM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is HTG Molecular Diagnostics' stock price today?

One share of HTGM stock can currently be purchased for approximately $3.53.

How big of a company is HTG Molecular Diagnostics?

HTG Molecular Diagnostics has a market capitalization of $96.13 million and generates $14.76 million in revenue each year. The medical research company earns $-18,960,000.00 in net income (profit) each year or ($1.79) on an earnings per share basis. HTG Molecular Diagnostics employs 98 workers across the globe.

How can I contact HTG Molecular Diagnostics?

HTG Molecular Diagnostics' mailing address is 3430 E. GLOBAL LOOP, TUCSON AZ, 85706. The medical research company can be reached via phone at 877-289-2615.


MarketBeat Community Rating for HTG Molecular Diagnostics (HTGM)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  153 (Vote Outperform)
Underperform Votes:  136 (Vote Underperform)
Total Votes:  289
MarketBeat's community ratings are surveys of what our community members think about HTG Molecular Diagnostics and other stocks. Vote "Outperform" if you believe HTGM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HTGM will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

HTG Molecular Diagnostics (NASDAQ:HTGM) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
3 Wall Street analysts have issued ratings and price targets for HTG Molecular Diagnostics in the last 12 months. Their average twelve-month price target is $6.6667, suggesting that the stock has a possible upside of 88.86%. The high price target for HTGM is $7.00 and the low price target for HTGM is $6.00. There are currently 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.002.672.67
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $6.6667$6.6667$5.6667$6.1667
Price Target Upside: 88.86% upside38.31% upside45.30% upside224.56% upside

HTG Molecular Diagnostics (NASDAQ:HTGM) Consensus Price Target History

Price Target History for HTG Molecular Diagnostics (NASDAQ:HTGM)

HTG Molecular Diagnostics (NASDAQ:HTGM) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/17/2018HC WainwrightSet Price TargetBuy$7.00HighView Rating Details
3/23/2018Canaccord GenuityBoost Price TargetBuy -> Buy$5.00 -> $7.00HighView Rating Details
5/16/2017Rodman & RenshawBoost Price TargetBuy -> Buy$4.50 -> $6.00HighView Rating Details
(Data available from 4/25/2016 forward)

Earnings

HTG Molecular Diagnostics (NASDAQ:HTGM) Earnings History and Estimates Chart

Earnings by Quarter for HTG Molecular Diagnostics (NASDAQ:HTGM)

HTG Molecular Diagnostics (NASDAQ:HTGM) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.66 EPS

HTG Molecular Diagnostics (NASDAQ HTGM) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/14/2018N/AView Earnings Details
3/22/2018Q4 2017($0.30)($0.15)$7.05 million$7.90 millionViewListenView Earnings Details
11/7/2017Q3 2017($0.49)($0.46)$3.20 million$3.72 millionViewN/AView Earnings Details
8/8/2017Q2($0.60)($0.60)$1.80 million$1.76 millionViewListenView Earnings Details
5/15/2017Q1($0.58)($0.73)$2.44 million$1.37 millionViewN/AView Earnings Details
3/23/2017Q4 2016($0.79)($0.76)$2.22 million$1.46 millionViewN/AView Earnings Details
11/14/2016Q3 2016($0.87)($0.92)$2.05 million$0.91 millionViewListenView Earnings Details
8/9/2016Q2($0.95)($0.98)$1.90 millionViewListenView Earnings Details
5/12/2016Q1($0.83)($1.02)$1.23 million$0.87 millionViewListenView Earnings Details
3/24/2016Q4($0.79)($0.83)$1.31 million$1.22 millionViewListenView Earnings Details
11/12/2015Q315($0.85)($0.76)$1.07 million$1.00 millionViewListenView Earnings Details
8/6/2015Q215($0.71)($1.73)$1.01 million$0.79 millionViewListenView Earnings Details
6/1/2015Q115($14.99)$1.00 millionViewListenView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

HTG Molecular Diagnostics (NASDAQ:HTGM) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

HTG Molecular Diagnostics (NASDAQ HTGM) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 7.60%
Institutional Ownership Percentage: 7.49%
Insider Trading History for HTG Molecular Diagnostics (NASDAQ:HTGM)
Institutional Ownership by Quarter for HTG Molecular Diagnostics (NASDAQ:HTGM)

HTG Molecular Diagnostics (NASDAQ HTGM) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/1/2017Shaun D McmeansVPSell945$2.11$1,993.95View SEC Filing  
11/1/2017Shaun D McmeansCFOSell945$2.26$2,135.7043,248View SEC Filing  
10/16/2017Shaun D McmeansVPSell946$2.27$2,147.4244,193View SEC Filing  
8/25/2017Holdings A/S NovoMajor ShareholderSell1,149,813$1.81$2,081,161.53View SEC Filing  
8/24/2017Holdings A/S NovoMajor ShareholderSell382,437$1.91$730,454.67View SEC Filing  
8/23/2017Holdings A/S NovoMajor ShareholderSell47,162$2.02$95,267.24View SEC Filing  
8/22/2017Holdings A/S NovoMajor ShareholderSell80,586$2.07$166,813.021,225,085View SEC Filing  
3/27/2017Plc GlaxosmithklineInsiderSell300,000$10.15$3,045,000.00View SEC Filing  
4/4/2016Debra A GordonVPSell1,672$2.89$4,832.0817,705View SEC Filing  
4/4/2016John L LubniewskiInsiderSell796$2.89$2,300.4425,114View SEC Filing  
4/4/2016Shaun D McmeansCFOSell1,601$2.89$4,626.8920,151View SEC Filing  
4/4/2016Tim B JohnsonCEOSell4,914$2.89$14,201.4651,309View SEC Filing  
3/14/2016Debra A GordonVPSell5,535$2.38$13,173.3023,518View SEC Filing  
3/14/2016John L LubniewskiInsiderSell6,889$2.38$16,395.8231,200View SEC Filing  
3/14/2016Patrick C RocheSVPSell5,929$2.38$14,111.0223,783View SEC Filing  
3/14/2016Shaun D McmeansCFOSell5,651$2.38$13,449.3825,991View SEC Filing  
3/14/2016Tim B JohnsonCEOSell10,621$2.38$25,277.9863,964View SEC Filing  
3/9/2016Debra A GordonVPSell3,256$2.69$8,758.6424,729View SEC Filing  
3/9/2016John L LubniewskiInsiderSell4,067$2.69$10,940.2332,712View SEC Filing  
3/9/2016Patrick C RocheSVPSell3,491$2.69$9,390.7925,081View SEC Filing  
3/9/2016Shaun D McmeansCFOSell3,325$2.69$8,944.2527,228View SEC Filing  
3/9/2016Tim B JohnsonCEOSell6,299$2.69$16,944.3166,306View SEC Filing  
8/24/2015Debra A GordonVPBuy1,000$5.16$5,160.001,356View SEC Filing  
8/18/2015Patrick C. RocheSVPBuy6,500$5.76$37,440.006,500View SEC Filing  
8/11/2015John L LubniewskiInsiderBuy5,000$7.67$38,350.00View SEC Filing  
5/11/2015A/S NovoMajor ShareholderBuy365,106$14.00$5,111,484.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

HTG Molecular Diagnostics (NASDAQ HTGM) News Headlines

Source:
DateHeadline
2 Attractive Biotechs Under $52 Attractive Biotechs Under $5
seekingalpha.com - April 24 at 5:35 PM
Financial Comparison: HTG Molecular Diagnostics (HTGM) versus Its RivalsFinancial Comparison: HTG Molecular Diagnostics (HTGM) versus Its Rivals
www.americanbankingnews.com - April 24 at 1:18 AM
Comparing HTG Molecular Diagnostics (HTGM) and Its PeersComparing HTG Molecular Diagnostics (HTGM) and Its Peers
www.americanbankingnews.com - April 20 at 9:22 PM
Analyzing HTG Molecular Diagnostics (HTGM) and Its CompetitorsAnalyzing HTG Molecular Diagnostics (HTGM) and Its Competitors
www.americanbankingnews.com - April 20 at 3:13 AM
HTG Molecular Diagnostics (HTGM) PT Set at $7.00 by HC WainwrightHTG Molecular Diagnostics (HTGM) PT Set at $7.00 by HC Wainwright
www.americanbankingnews.com - April 18 at 8:36 AM
HTG Molecular Diagnostics (HTGM) Stock Rating Upgraded by ValuEngineHTG Molecular Diagnostics (HTGM) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - April 17 at 10:55 PM
HTG Molecular Diagnostics (HTGM) Upgraded by Zacks Investment Research to "Hold"HTG Molecular Diagnostics (HTGM) Upgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - April 17 at 4:47 PM
HTG Molecular Diagnostics (HTGM) Announces Promotion of John Lubniewski to President & COOHTG Molecular Diagnostics (HTGM) Announces Promotion of John Lubniewski to President & COO
www.streetinsider.com - April 16 at 5:24 PM
HTG Promotes John Lubniewski to President and Chief Operating OfficerHTG Promotes John Lubniewski to President and Chief Operating Officer
finance.yahoo.com - April 16 at 5:24 PM
Comparing HTG Molecular Diagnostics (HTGM) & The CompetitionComparing HTG Molecular Diagnostics (HTGM) & The Competition
www.americanbankingnews.com - April 13 at 3:24 PM
HTG Molecular Diagnostics (HTGM) Given a $6.00 Price Target by HC Wainwright AnalystsHTG Molecular Diagnostics (HTGM) Given a $6.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - April 11 at 11:52 PM
HTG Molecular Diagnostics (HTGM) vs. Its Peers Financial AnalysisHTG Molecular Diagnostics (HTGM) vs. Its Peers Financial Analysis
www.americanbankingnews.com - April 11 at 5:31 AM
Comparing HTG Molecular Diagnostics (HTGM) & Its CompetitorsComparing HTG Molecular Diagnostics (HTGM) & Its Competitors
www.americanbankingnews.com - April 11 at 3:17 AM
HTG Molecular Diagnostics (HTGM) Cut to "Sell" at Zacks Investment ResearchHTG Molecular Diagnostics (HTGM) Cut to "Sell" at Zacks Investment Research
www.americanbankingnews.com - April 10 at 1:42 PM
Head-To-Head Survey: HTG Molecular Diagnostics (HTGM) & Its PeersHead-To-Head Survey: HTG Molecular Diagnostics (HTGM) & Its Peers
www.americanbankingnews.com - April 10 at 1:30 AM
ValuEngine Lowers HTG Molecular Diagnostics (HTGM) to Strong SellValuEngine Lowers HTG Molecular Diagnostics (HTGM) to Strong Sell
www.americanbankingnews.com - April 7 at 8:50 PM
HTG Molecular Diagnostics (HTGM) Upgraded to "Sell" at ValuEngineHTG Molecular Diagnostics (HTGM) Upgraded to "Sell" at ValuEngine
www.americanbankingnews.com - April 6 at 11:39 AM
Reviewing HTG Molecular Diagnostics (HTGM) & Mettler-Toledo International (MTD)Reviewing HTG Molecular Diagnostics (HTGM) & Mettler-Toledo International (MTD)
www.americanbankingnews.com - April 5 at 12:11 PM
Head to Head Contrast: HTG Molecular Diagnostics (HTGM) vs. Bruker (BRKR)Head to Head Contrast: HTG Molecular Diagnostics (HTGM) vs. Bruker (BRKR)
www.americanbankingnews.com - April 3 at 7:33 PM
HTG Announces New Patent for Its Technology Issued in JapanHTG Announces New Patent for Its Technology Issued in Japan
finance.yahoo.com - April 3 at 8:24 AM
HTG Molecular Diagnostics (HTGM) Buy Rating Reaffirmed at HC WainwrightHTG Molecular Diagnostics' (HTGM) Buy Rating Reaffirmed at HC Wainwright
www.americanbankingnews.com - April 1 at 10:29 AM
HTG Molecular Diagnostics (HTGM) Stock Rating Upgraded by Zacks Investment ResearchHTG Molecular Diagnostics (HTGM) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - March 29 at 7:58 PM
HTG Molecular Diagnostics (HTGM) Stock Rating Lowered by Zacks Investment ResearchHTG Molecular Diagnostics (HTGM) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - March 28 at 11:56 AM
HTG Molecular Diagnostics (HTGM) Rating Increased to Buy at Zacks Investment ResearchHTG Molecular Diagnostics (HTGM) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - March 27 at 10:56 PM
HTG Molecular Diagnostics (HTGM) Cut to Hold at Zacks Investment ResearchHTG Molecular Diagnostics (HTGM) Cut to Hold at Zacks Investment Research
www.americanbankingnews.com - March 27 at 1:16 PM
HTG Molecular Diagnostics Secures Debt Facility with MidCap FinancialHTG Molecular Diagnostics Secures Debt Facility with MidCap Financial
finance.yahoo.com - March 27 at 8:27 AM
HC Wainwright Reaffirms Buy Rating for HTG Molecular Diagnostics (HTGM)HC Wainwright Reaffirms Buy Rating for HTG Molecular Diagnostics (HTGM)
www.americanbankingnews.com - March 25 at 10:56 PM
HTG Molecular Diagnostics (HTGM) Upgraded by Zacks Investment Research to "Buy"HTG Molecular Diagnostics (HTGM) Upgraded by Zacks Investment Research to "Buy"
www.americanbankingnews.com - March 23 at 11:52 PM
HTG Molecular Diagnostics (HTGM) Price Target Raised to $7.00 at Canaccord GenuityHTG Molecular Diagnostics (HTGM) Price Target Raised to $7.00 at Canaccord Genuity
www.americanbankingnews.com - March 23 at 3:16 PM
HTG Molecular Diagnostics (HTGM) PT Raised to $7 at Canaccord Genuity - StreetInsider.comHTG Molecular Diagnostics (HTGM) PT Raised to $7 at Canaccord Genuity - StreetInsider.com
www.streetinsider.com - March 23 at 8:19 AM
HTG Molecular Diagnostics (HTGM) CEO TJ Johnson on Q4 2017 Results - Earnings Call Transcript - Seeking AlphaHTG Molecular Diagnostics' (HTGM) CEO TJ Johnson on Q4 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - March 23 at 8:19 AM
3 Stocks to Watch on Friday: At Home Group Inc (HOME), HTG Molecular Diagnostics Inc (HTGM) and iCAD Inc (ICAD) - Investorplace.com3 Stocks to Watch on Friday: At Home Group Inc (HOME), HTG Molecular Diagnostics Inc (HTGM) and iCAD Inc (ICAD) - Investorplace.com
investorplace.com - March 23 at 8:19 AM
HTG Molecular Diagnostics (HTGM) Posts Quarterly  Earnings Results, Beats Expectations By $0.15 EPSHTG Molecular Diagnostics (HTGM) Posts Quarterly Earnings Results, Beats Expectations By $0.15 EPS
www.americanbankingnews.com - March 23 at 8:14 AM
3 Stocks to Watch on Friday: At Home Group Inc (HOME), HTG Molecular Diagnostics Inc (HTGM) and iCAD Inc (ICAD)3 Stocks to Watch on Friday: At Home Group Inc (HOME), HTG Molecular Diagnostics Inc (HTGM) and iCAD Inc (ICAD)
investorplace.com - March 23 at 7:33 AM
HTG Molecular Diagnostics (HTGM) Rating Lowered to Hold at Zacks Investment ResearchHTG Molecular Diagnostics (HTGM) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - March 23 at 12:30 AM
Earnings Scheduled For March 22, 2018 - BenzingaEarnings Scheduled For March 22, 2018 - Benzinga
www.benzinga.com - March 22 at 5:36 PM
HTG Molecular Diagnostics Reports Fourth Quarter and Full Year 2017 Results - GlobeNewswire (press release)HTG Molecular Diagnostics Reports Fourth Quarter and Full Year 2017 Results - GlobeNewswire (press release)
globenewswire.com - March 22 at 5:36 PM
HTG Molecular Diagnostics Reports Fourth Quarter and Full Year 2017 ResultsHTG Molecular Diagnostics Reports Fourth Quarter and Full Year 2017 Results
finance.yahoo.com - March 22 at 5:36 PM
Square Is One of 4 Upset Picks in Our Latest Sweet 16 Stock SelectionsSquare Is One of 4 Upset Picks in Our Latest 'Sweet 16' Stock Selections
finance.yahoo.com - March 20 at 5:17 PM
Recent Analysis Shows Iridium Communications, TPI Composites, First Internet, Destination Maternity, HTG Molecular Diagnostics, and 8x8 Market Influences — Renewed Outlook, Key Drivers of GrowthRecent Analysis Shows Iridium Communications, TPI Composites, First Internet, Destination Maternity, HTG Molecular Diagnostics, and 8x8 Market Influences — Renewed Outlook, Key Drivers of Growth
finance.yahoo.com - March 19 at 8:23 AM
HTG Molecular Diagnostics (HTGM) Scheduled to Post Quarterly Earnings on ThursdayHTG Molecular Diagnostics (HTGM) Scheduled to Post Quarterly Earnings on Thursday
www.americanbankingnews.com - March 16 at 8:12 PM
HTG Molecular Diagnostics to Announce Fourth Quarter and Year-End Financial Results and Host Conference Call on Thursday, March 22HTG Molecular Diagnostics to Announce Fourth Quarter and Year-End Financial Results and Host Conference Call on Thursday, March 22
finance.yahoo.com - March 7 at 6:34 PM
HTG Announces New Australian Patent for Its TechnologyHTG Announces New Australian Patent for Its Technology
finance.yahoo.com - March 6 at 8:15 AM
HTG Molecular Diagnostics (HTGM) Announces New Australian PatentHTG Molecular Diagnostics (HTGM) Announces New Australian Patent
www.streetinsider.com - February 27 at 5:55 PM
HTG Molecular Diagnostics (HTGM) Announces New Australian Patent - StreetInsider.comHTG Molecular Diagnostics (HTGM) Announces New Australian Patent - StreetInsider.com
www.streetinsider.com - February 27 at 8:19 AM
4 Stocks to Watch on News & Technical Momentum4 Stocks to Watch on News & Technical Momentum
www.nasdaq.com - February 14 at 4:04 PM
HTG Molecular Diagnostics to Present at the LEERINK Partners 7th Annual Global Healthcare ConferenceHTG Molecular Diagnostics to Present at the LEERINK Partners 7th Annual Global Healthcare Conference
finance.yahoo.com - February 7 at 9:40 AM
HC Wainwright Analysts Give HTG Molecular Diagnostics (HTGM) a $6.00 Price TargetHC Wainwright Analysts Give HTG Molecular Diagnostics (HTGM) a $6.00 Price Target
www.americanbankingnews.com - January 28 at 5:10 PM
HTG Molecular Diagnostics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional SharesHTG Molecular Diagnostics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares
finance.yahoo.com - January 23 at 5:26 PM
HTG Molecular Diagnostics (HTGM) Prices 12M Share Common Offering at $2.90/ShHTG Molecular Diagnostics (HTGM) Prices 12M Share Common Offering at $2.90/Sh
www.streetinsider.com - January 21 at 5:16 PM

SEC Filings

HTG Molecular Diagnostics (NASDAQ:HTGM) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

HTG Molecular Diagnostics (NASDAQ:HTGM) Income Statement, Balance Sheet and Cash Flow Statement

Chart

HTG Molecular Diagnostics (NASDAQ HTGM) Stock Chart for Wednesday, April, 25, 2018

Loading chart…

This page was last updated on 4/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.